IGC Pharma

As of 2023, the estimated number of Americans living with Alzheimer's disease was 6.7 million. However, a lesser-known subsection of Alzheimer's is Agitation in dementia from Alzheimer's Disease (AAD). Recent research suggests that up to 76% of individuals with Alzheimer’s also suffer from...

In a massive stride towards Alzheimer’s treatment, IGC Pharma (NYSE:IGC) recently revealed promising interim results for their pioneering drug, IGC-AD1, aimed at mitigating agitation in Alzheimer’s patients. This breakthrough is a beacon of hope for millions affected by this...

Circle March 20 on your calendars! Starting at 10:25 a.m. EST Wednesday, the Benzinga Virtual Healthcare Summit 2024 is the place to be. Imagine a digital room buzzing with the likes of Beachbody’s Mark Goldston, Autonomix Medical’s Lori Bisson, and IGC Pharma’s Ram Mukunda (NYSE:...

IGC Pharma Inc (AMEX:IGC) recently entered into a Master Cooperation Agreement with the University of Los Andes, focusing on integrating generative AI solutions into various aspects of drug development and clinical trials.  This collaboration aims to enhance the efficiency of clinical trials,...

IGC Pharma, Inc. (IGC), a leading cannabinoid-based formulation developer, has expanded its Phase 2 clinical trial for IGC-AD1, a natural THC-based investigational drug for Alzheimer's disease, to the University of Puerto Rico network. IGC is dedicated to developing advanced cannabinoid-based...

India Globalization Capital, Inc. (AMEX:IGC) announced that the United States Patent and Trademark Office issued a second patent (#11,446,276) for the treatment of Alzheimer’s disease entitled “Extreme low dose THC as a therapeutic and prophylactic agent for Alzheimer’s disease....